AT
Actinium Pharmaceuticals, Inc.
ATNM · AMEX
$1.21 +1.26% (+$0.02)
1M +10.91%
Market Cap $37.6M
P/E Ratio 3.33x
Div. Yield -
ROE 83.42%
Bulios Fair Price
$1.49
23.7% upside
Trenutna cena
$1.21
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica ATNM trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Moderate
4/9Valuation
100 /100
Cheap P/E 3.33x
P/B 1.24x
EV/EBITDA 0.21x
Growth
0 /100
Declining Rev. growth 55.63%
Book val. growth 50.97%
EPS growth N/A
Profitability
70 /100
Strong Gross margin 101.13%
FCF margin 66.25%
Net margin 32.23%
Quality
96 /100
Excellent ROIC 30.20%
Asset turnover 0.87x
ROE 83.42%
Debt
100 /100
Low Debt/Equity 0.04x
Net debt/EBITDA -2.88x
Current ratio 4.08x
Stability
27 /100
Unstable Beta 0.02x
Profitable years 0
EPS volatility 33.34%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o ATNM
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Sandesh C. Seth
Employees
27
Headquarters
New York City
Prihajajoči dogodki
13 NOV.
Earnings
Upcoming earnings report